<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01515410</url>
  </required_header>
  <id_info>
    <org_study_id>81-0068</org_study_id>
    <nct_id>NCT01515410</nct_id>
  </id_info>
  <brief_title>Study in Advanced Parkinson's Disease Patients With Predictable Motor Fluctuations</brief_title>
  <official_title>A Phase 2, Randomized, Open-Label, Crossover Study to Compare DM-1992, a Novel Gastric-Retentive Extended-Release Formulation of Levodopa/Carbidopa, to an Immediate-Release Carbidopa Tablet in Patients With Advanced Parkinson's Disease With Motor Fluctuations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Depomed</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Depomed</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to explore the efficacy and tolerability of DM-1992
      compared to a standard carbidopa/Levodopa Immediate-Release (CD/LD IR) tablet (Sinemet IR) as
      measured by:

        -  &quot;ON&quot; time with no dyskinesia or non-troublesome dyskinesia

        -  &quot;OFF&quot; time
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Primary Objective of This Study is to Explore the Efficacy and Tolerability of DM-1992 Compared to a Standard CD/LD IR Formulation as Measured by Percent &quot;OFF&quot; Time.</measure>
    <time_frame>Baseline and 10 days for each of the 2 study periods</time_frame>
    <description>&quot;OFF&quot; indicates wearing off motor fluctuations before the next levodopa dose. Percent &quot;OFF&quot; time is calculated as the total &quot;OFF&quot; time divided by the total awake time for each day and multiplied by 100.
Patient diary-every 30min while awake for 3days prior to initial Day1 as baseline &amp; during the last 3days before Day10 for both treatments for dyskinesia state.
Baseline is the average of the 3 days recorded in the patient diary prior to Day 1 of Period 1.
End of Period is the average of the 3 days recorded in the patient diary prior to Day 10 in each period.
Clinician-Assess efficacy at pre-dose, every 30min for Day1 and hourly for Day10 for dyskinesia state &amp; motor fluctuations at clinic visits.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Parkinson's Disease</condition>
  <condition>Motor Fluctuations</condition>
  <arm_group>
    <arm_group_label>DM-1992</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DM-1992, a gastric-retentive extended-release tablet containing 72.5mg carbidopa (CD) and 230mg levodopa (LD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sinemet IR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>An Immediate-release (IR) tablet containing 25mg carbidopa (CD) and 100mg levodopa (LD)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DM-1992</intervention_name>
    <description>72.5mg carbidopa/230mg levodopa</description>
    <arm_group_label>DM-1992</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sinemet IR</intervention_name>
    <description>Immediate-release tablet containing 25mg carbidopa and 100mg levodopa</description>
    <arm_group_label>Sinemet IR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women at least 30 years and older at the time of informed consent with
             advanced idiopathic Parkinson's disease with predictable wearing-off motor
             fluctuations with Hoehn and Yahr Stage II-III when &quot;on.&quot;

          2. Patients should be able to differentiate between the &quot;ON&quot; and &quot;OFF&quot; states with an
             average daily &quot;OFF&quot; time of ≥ 2.5 hours at study entry.

          3. On a stable daily dose of LD of ≥ 400 mg but ≤1600 mg for at least 1 month prior to
             the screening visit.

          4. Non CD/LD containing anti-Parkinson's medications should be kept at stable doses for 1
             month prior to screening visit. Patients should be willing to keep their non LD
             containing medications consistently throughout the study duration.

          5. Female patients of childbearing potential should be abstinent or continuing to
             practice and willing to continue throughout the study with appropriate contraceptives
             (defined as Nova ring, oral, injected, transdermal patch, implanted, or barrier).

          6. Mini Mental State Examination (MMSE) ≥ 26 at screening visit.

          7. Able to provide informed consent and willing to sign Health Insurance Portability and
             Accountability Act (HIPAA) authorization.

          8. Able and willing to comply with the protocol, including availability for all scheduled
             study visits and blood sample collections. Must be under the observation of a
             competent care giver throughout the study participation.

        Exclusion Criteria:

          1. Patients with atypical or drug-induced Parkinson's disease.

          2. Patients with a known history of hypersensitivity to levodopa or carbidopa.

          3. Patients who receive treatments with dopamine receptor blocking agents

          4. Patients with a history of seizures except of childhood febrile seizure.

          5. Patients with dementia.

          6. Patients with a significant history of GI diseases (severe inflammatory bowel disease,
             irritable bowel disease, dyspepsia, gastro-esophageal reflux disease etc.) in the past
             five years.

          7. Patients with any history of gastric surgery other than vagotomy and pyloroplasty.

          8. Patients with an immune-compromised state.

          9. Patients with clinically significant hepatic insufficiency with Child-Pugh total score
             of ≥ 5.

         10. Patients with a calculated creatinine clearance (Clcr) &lt; 50 mL/min using the
             Cockcroft-Gault equation.

         11. Patients who have a difficulty swallowing tablets.

         12. Patient has participated in a clinical trial of an investigational drug or device
             within 30 days of the screening visit.

         13. Patients with any other serious medical condition that, in the opinion of the
             Investigator would jeopardize the safety of the patient or affect the validity of the
             study results.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rekha Sathyanarayana</last_name>
    <role>Study Director</role>
    <affiliation>Depomed</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bingham Farms</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2012</study_first_submitted>
  <study_first_submitted_qc>January 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2012</study_first_posted>
  <results_first_submitted>November 20, 2013</results_first_submitted>
  <results_first_submitted_qc>January 27, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 10, 2014</results_first_posted>
  <last_update_submitted>January 27, 2014</last_update_submitted>
  <last_update_submitted_qc>January 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson's disease</keyword>
  <keyword>PD</keyword>
  <keyword>stage2/3Parkinson's</keyword>
  <keyword>Advanced Parkinson's Disease with Motor Fluctuations</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Carbidopa</mesh_term>
    <mesh_term>Carbidopa, levodopa drug combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 34 subjects were randomly assigned to treatment in this crossover study: 19 in the DM-1992 for Period 1 and Sinemet IR for Period 2 sequence, and 15 in the Sinemet IR for Period 1 and DM-1992 for Period 2 sequence. All 34 subjects received study treatment and were included in the safety and intent-to-treat (ITT) populations.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>DM-1992 First, Then Sinemet IR</title>
          <description>DM-1992, a gastric-retentive extended-release tablet containing 72.5mg carbidopa (CD) and 230mg levodopa (LD) first, then Sinemet IR, an Immediate-release (IR) tablet containing 25mg carbidopa (CD) and 100mg levodopa (LD)</description>
        </group>
        <group group_id="P2">
          <title>Sinemet IR First, Then DM-1992</title>
          <description>Sinemet IR, an Immediate-release (IR) tablet containing 25mg carbidopa (CD) and 100mg levodopa (LD) first, then DM-1992, a gastric-retentive extended-release tablet containing 72.5mg carbidopa (CD) and 230mg levodopa (LD)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Overall Study</title>
          <description>DM-1992 first, then Sinemet IR; Sinemet IR first, then DM-1992</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.4" spread="8.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Afro-Caribbean</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaskan Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Percent &quot;OFF&quot; Time (%)</title>
          <description>Baseline is the average of the 3 days recorded in the patient diary prior to Day 1 of Period 1.</description>
          <units>percentage of time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.50" spread="9.962"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Primary Objective of This Study is to Explore the Efficacy and Tolerability of DM-1992 Compared to a Standard CD/LD IR Formulation as Measured by Percent &quot;OFF&quot; Time.</title>
        <description>&quot;OFF&quot; indicates wearing off motor fluctuations before the next levodopa dose. Percent &quot;OFF&quot; time is calculated as the total &quot;OFF&quot; time divided by the total awake time for each day and multiplied by 100.
Patient diary-every 30min while awake for 3days prior to initial Day1 as baseline &amp; during the last 3days before Day10 for both treatments for dyskinesia state.
Baseline is the average of the 3 days recorded in the patient diary prior to Day 1 of Period 1.
End of Period is the average of the 3 days recorded in the patient diary prior to Day 10 in each period.
Clinician-Assess efficacy at pre-dose, every 30min for Day1 and hourly for Day10 for dyskinesia state &amp; motor fluctuations at clinic visits.</description>
        <time_frame>Baseline and 10 days for each of the 2 study periods</time_frame>
        <population>Modified Intent-to-treat (ITT) Population</population>
        <group_list>
          <group group_id="O1">
            <title>DM-1992</title>
            <description>DM-1992, a gastric-retentive extended-release tablet containing 72.5mg carbidopa (CD) and 230mg levodopa (LD)</description>
          </group>
          <group group_id="O2">
            <title>Sinemet IR</title>
            <description>Sinemet IR, an Immediate-release (IR) tablet containing 25mg carbidopa (CD) and 100mg levodopa (LD)</description>
          </group>
        </group_list>
        <measure>
          <title>The Primary Objective of This Study is to Explore the Efficacy and Tolerability of DM-1992 Compared to a Standard CD/LD IR Formulation as Measured by Percent &quot;OFF&quot; Time.</title>
          <description>&quot;OFF&quot; indicates wearing off motor fluctuations before the next levodopa dose. Percent &quot;OFF&quot; time is calculated as the total &quot;OFF&quot; time divided by the total awake time for each day and multiplied by 100.
Patient diary-every 30min while awake for 3days prior to initial Day1 as baseline &amp; during the last 3days before Day10 for both treatments for dyskinesia state.
Baseline is the average of the 3 days recorded in the patient diary prior to Day 1 of Period 1.
End of Period is the average of the 3 days recorded in the patient diary prior to Day 10 in each period.
Clinician-Assess efficacy at pre-dose, every 30min for Day1 and hourly for Day10 for dyskinesia state &amp; motor fluctuations at clinic visits.</description>
          <population>Modified Intent-to-treat (ITT) Population</population>
          <units>percentage of time</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.52" lower_limit="-10.42" upper_limit="-0.63"/>
                    <measurement group_id="O2" value="1.33" lower_limit="-3.56" upper_limit="6.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percent &quot;OFF&quot; Time (%)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0471</p_value>
            <p_value_desc>This p-value indicates statistical significance at the 0.05 level.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>No subjects early-terminated from the study.</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-6.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-13.62</ci_lower_limit>
            <ci_upper_limit>-0.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events collected for a total of 5-6 weeks: from after signing the informed consent to the end of the study (Period 2, Day 10).</time_frame>
      <desc>Adverse event collection began after signing the informed consent and continued through Period 2, Day 10; serious adverse events followed for 30 days after study completion.</desc>
      <group_list>
        <group group_id="E1">
          <title>DM-1992</title>
          <description>DM-1992, a gastric-retentive extended-release tablet containing 72.5mg carbidopa (CD) and 230mg levodopa (LD)</description>
        </group>
        <group group_id="E2">
          <title>Sinemet IR</title>
          <description>Sinemet IR, an Immediate-release (IR) tablet containing 25mg carbidopa (CD) and 100mg levodopa (LD)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Parkinsonian gait</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Hypertonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PI agrees that sponsor shall have the right to the first publication of the study results which is intended to be a joint, multi-center publication. Following the first publication, the PI may publish study data or results, provided however PI submits the proposed publication to sponsor for review at least 60 days prior to the date of the proposed publication. Sponsor may remove any information that is considered confidential and/or proprietary other than study data.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Head of R&amp;D</name_or_title>
      <organization>Depomed</organization>
      <phone>510-744-8000</phone>
      <email>msweeney@depomed.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

